Hologic (HOLX) director Nanaz Mohtashami receives 3,190 restricted stock units

Rhea-AI Filing Summary

Hologic Inc. director Nanaz Mohtashami received an equity award in the form of restricted stock units. On the reported date, she acquired 3,190 RSUs at no cash cost, classified as a grant or award acquisition. Following this grant, she now holds 7,371 shares of common stock in direct ownership.

The footnotes explain that these RSUs will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders and will be settled in shares of common stock on a one-for-one basis, linking director compensation directly to future stock performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohtashami Nanaz

(Last) (First) (Middle)

250 CAMPUS DRIVE

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HOLOGIC INC [ HOLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		3,190(1)	A	(2)	7,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.

2. Restricted stock units are settled in shares of common stock on a one-for-one basis.

	/s/ Mark W. Irving, attorney-in-fact for Ms. Mohtashami	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Hologic (HOLX) report for Nanaz Mohtashami?

Hologic reported that director Nanaz Mohtashami acquired 3,190 restricted stock units as an equity award. These RSUs were granted at a price of $0.0000 per share and increased her directly owned common stock position to 7,371 shares after the transaction.

How many Hologic (HOLX) shares does Nanaz Mohtashami own after this Form 4?

After the reported grant, Nanaz Mohtashami beneficially owns 7,371 shares of Hologic common stock in direct ownership. This total reflects the addition of 3,190 restricted stock units that were granted and will ultimately settle in common shares on a one-for-one basis.

What type of award did Hologic (HOLX) grant to director Nanaz Mohtashami?

Hologic granted restricted stock units to director Nanaz Mohtashami, classified as a grant, award, or other acquisition under transaction code A. The award covers 3,190 RSUs that convert into common stock on a one-for-one basis when they are ultimately settled.

When do Nanaz Mohtashami’s Hologic (HOLX) restricted stock units vest?

The restricted stock units granted to Nanaz Mohtashami vest on the date of Hologic’s 2027 Annual Meeting of Stockholders. At that time, the RSUs are scheduled to be settled in an equivalent number of Hologic common shares, aligning director incentives with long-term shareholder value.

Did Nanaz Mohtashami pay cash for the Hologic (HOLX) shares reported on Form 4?

No cash payment was indicated for this transaction; the 3,190 restricted stock units were granted at a reported price of $0.0000 per share. This reflects a typical equity compensation award structure for directors, rather than an open-market purchase of Hologic common stock.